DEFA14A: Exact Sciences Accelerates Executive Pay Ahead of Abbott Merger

Exact Sciences Corporation accelerates 2025 annual bonuses and equity awards for its named executive officers to mitigate tax impacts related to its pending merger with Abbott Laboratories.

Summary

• Exact Sciences Corporation (Exact) previously announced an Agreement and Plan of Merger with Abbott Laboratories (Parent) and Badger Merger Sub I, Inc. (Merger Sub) on November 19, 2025.
• The Human Capital Committee of Exact's Board of Directors approved the acceleration of vesting and payment of fiscal year 2025 annual bonuses and certain restricted stock unit (RSU) and performance share unit (PSU) awards for its active named executive officers (NEOs).
• This action aims to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986 on Exact and its employees.
• For the Accelerated 2025 Annual Bonus, performance is deemed to be 115% of the target level.
• For Exact PSU Awards, vesting is based on specific target levels: 225% for 2023 grants, 104% for 2024 grants, and 218% for 2025 grants.
• Acceleration and Clawback Agreements were entered into on December 23, 2025, outlining the terms of these accelerated payments.
• Accelerated payments are subject to repayment if an NEO's employment terminates under circumstances that would have resulted in forfeiture had the amounts not been vested or paid early.
• If actual performance for 2025 annual bonuses or accelerated Exact PSU Awards (if the merger is terminated) exceeds the accelerated levels, Exact will pay the NEOs the difference.

Sentiment

Score: 6

Explanation: The filing details standard, proactive measures taken by Exact Sciences to manage executive compensation and tax implications in anticipation of an announced merger. While it involves significant executive payouts, the presence of clawback provisions and the strategic intent to retain talent and mitigate tax risks are generally viewed as prudent steps in an M&A context, contributing to deal stability.

Positives

• Proactive mitigation of potential adverse tax impacts (Sections 280G and 4999) for Exact and its named executive officers, which can streamline the merger process.
• Provides compensation certainty and aims to retain key executive talent during the transition period leading up to the merger with Abbott Laboratories.
• Clawback provisions are in place, requiring repayment of accelerated amounts under specific termination conditions, offering some protection for the company.

Negatives

• Significant compensation payouts to executives are being made ahead of the merger's completion, representing a cash outflow or share issuance.
• The 'deemed' performance levels for accelerated bonuses and PSUs (e.g., 115% for annual bonus, 225% for 2023 PSUs) might not align with actual performance if the merger were to be terminated.

Risks

• Potential for excise tax on employees under Section 4999 of the Internal Revenue Code, despite mitigation efforts, if payments are deemed 'excess parachute payments'.
• Named Executive Officers face a repayment obligation for accelerated amounts if their employment terminates under specific forfeiture-triggering circumstances prior to the original vesting/payment date.
• The proposed merger with Abbott Laboratories is subject to various conditions, and its completion is not guaranteed.

Future Outlook

The proposed merger with Abbott Laboratories is pending and subject to the conditions outlined in the Merger Agreement. Upon completion, Exact Sciences will survive as an indirect, wholly-owned subsidiary of Abbott Laboratories.

Management Comments

• The Human Capital Committee of the Board of Directors of Exact, with the advice of Exact's Section 280G consultant, approved the actions to mitigate potential tax impacts.
• Aaron Bloomer, Executive Vice President and Chief Financial Officer, signed the report on behalf of Exact Sciences Corporation.

Industry Context

na

Corporate Governance

Legal Proceedings

• Any controversy arising out of or relating to the Acceleration and Clawback Agreement that cannot be resolved by the employee and the Company shall be submitted to final and binding arbitration administered by JAMS.

Related Party Transactions

• Acceleration of 2025 annual bonuses and certain restricted stock unit and performance share unit awards for Named Executive Officers, who are related parties, in anticipation of the merger with Abbott Laboratories.

Stakeholder Impact

• Shareholders: Will receive a proxy statement with important information regarding the proposed transaction. The accelerated compensation represents a cost associated with the merger but is intended to ensure executive stability.
• Named Executive Officers (NEOs): Benefit from accelerated vesting and payment of bonuses and equity, with provisions designed to mitigate personal tax impacts. They are subject to clawback provisions under specific termination conditions.
• Abbott Laboratories (Parent): The acquiring entity, which benefits from the pre-merger planning to ensure executive retention and manage tax liabilities of the target company's leadership.

Next Steps

• Exact will file a proxy statement with the U.S. Securities and Exchange Commission (SEC) regarding the proposed transaction.
• Investors and security holders are urged to read the proxy statement and any other relevant documents filed with the SEC carefully.
• Named Executive Officers are required to make an 83(b) Election with the IRS on or before the 30th day following the Acceleration Date (December 23, 2025).
• The closing of the merger with Abbott Laboratories is pending and subject to the conditions in the Merger Agreement.

Key Dates

Recommendation

This filing details standard executive compensation adjustments in anticipation of an already announced merger. It does not present new information that would fundamentally alter the investment thesis for Exact Sciences, which is primarily driven by the pending acquisition by Abbott Laboratories. Investors should hold their position pending the merger's completion, as the current news is procedural rather than indicative of new operational performance or strategic shifts.

Keywords

Exact Sciences, Abbott Laboratories, Merger, Executive Compensation, Section 280G, Section 4999, Parachute Payments, Restricted Stock Units, Performance Share Units, Annual Bonus, Corporate Governance, SEC Filing, Form 8-K